Cargando…
Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients
PURPOSE: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: The 2020 Metab...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022408/ https://www.ncbi.nlm.nih.gov/pubmed/35445967 http://dx.doi.org/10.1007/s11695-022-06068-y |
_version_ | 1784690077785391104 |
---|---|
author | Verhoeff, Kevin Mocanu, Valentin Jogiat, Uzair Forbes, Hayley Switzer, Noah J. Birch, Daniel W. Karmali, Shahzeer |
author_facet | Verhoeff, Kevin Mocanu, Valentin Jogiat, Uzair Forbes, Hayley Switzer, Noah J. Birch, Daniel W. Karmali, Shahzeer |
author_sort | Verhoeff, Kevin |
collection | PubMed |
description | PURPOSE: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: The 2020 Metabolic and Bariatric Accreditation and Quality Improvement Program (MBSAQIP) registry was analyzed, comparing SADI-S to RYGB. Bivariate analysis was performed to determine intergroup differences. Multivariable logistic regression determined factors associated with serious complications and mortality. RESULTS: We evaluated 47,375 patients, with 501 (1.1%) receiving SADI-S. Patients undergoing SADI-S had higher body mass index (51.4 ± 9.7 kg/m(2) SADI-S vs. 44.6 ± 7.9 kg/m(2) RYGB; p < 0.001), and more metabolic comorbidities including non-insulin dependent diabetes (21.7% SADI-S vs 19.0% RYGB; p = 0.011), insulin dependent diabetes (12.0% SADI-S vs. 8.6% RYGB; p = 0.011), and hypertension (54.9% SADI-S vs 47.6% RYGB; p < 0.001). Patients undergoing SADI-S experienced more anastomotic leaks (2.2% vs. 0.5%; p < 0.001), reoperations (5.0% vs 2.6%; p < 0.001), pneumonias (1.6% vs 0.5%; p < 0.001), had sepsis more frequently (1.4% vs 0.3%; p < 0.001), and required more unplanned reintubations (1.2% vs 0.3%; p = 0.004). SADI-S was independently associated with serious complications (OR 1.45, CI 1.09–1.95, p < 0.001) but was not a predictor of mortality (OR 3.29, p = 0.060). CONCLUSIONS: In comparison to RYGB, patients undergoing SADI-S were found to have more metabolic comorbidities. Compared to RYGB, SADI-S has worse perioperative outcomes and is independently associated with serious complications. It remains unclear whether this represents a learning curve or true findings and prospective studies analyzing the risk–benefit ratio following SADI-S are needed. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-9022408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90224082022-04-21 Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients Verhoeff, Kevin Mocanu, Valentin Jogiat, Uzair Forbes, Hayley Switzer, Noah J. Birch, Daniel W. Karmali, Shahzeer Obes Surg Original Contributions PURPOSE: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: The 2020 Metabolic and Bariatric Accreditation and Quality Improvement Program (MBSAQIP) registry was analyzed, comparing SADI-S to RYGB. Bivariate analysis was performed to determine intergroup differences. Multivariable logistic regression determined factors associated with serious complications and mortality. RESULTS: We evaluated 47,375 patients, with 501 (1.1%) receiving SADI-S. Patients undergoing SADI-S had higher body mass index (51.4 ± 9.7 kg/m(2) SADI-S vs. 44.6 ± 7.9 kg/m(2) RYGB; p < 0.001), and more metabolic comorbidities including non-insulin dependent diabetes (21.7% SADI-S vs 19.0% RYGB; p = 0.011), insulin dependent diabetes (12.0% SADI-S vs. 8.6% RYGB; p = 0.011), and hypertension (54.9% SADI-S vs 47.6% RYGB; p < 0.001). Patients undergoing SADI-S experienced more anastomotic leaks (2.2% vs. 0.5%; p < 0.001), reoperations (5.0% vs 2.6%; p < 0.001), pneumonias (1.6% vs 0.5%; p < 0.001), had sepsis more frequently (1.4% vs 0.3%; p < 0.001), and required more unplanned reintubations (1.2% vs 0.3%; p = 0.004). SADI-S was independently associated with serious complications (OR 1.45, CI 1.09–1.95, p < 0.001) but was not a predictor of mortality (OR 3.29, p = 0.060). CONCLUSIONS: In comparison to RYGB, patients undergoing SADI-S were found to have more metabolic comorbidities. Compared to RYGB, SADI-S has worse perioperative outcomes and is independently associated with serious complications. It remains unclear whether this represents a learning curve or true findings and prospective studies analyzing the risk–benefit ratio following SADI-S are needed. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2022-04-21 2022 /pmc/articles/PMC9022408/ /pubmed/35445967 http://dx.doi.org/10.1007/s11695-022-06068-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Contributions Verhoeff, Kevin Mocanu, Valentin Jogiat, Uzair Forbes, Hayley Switzer, Noah J. Birch, Daniel W. Karmali, Shahzeer Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients |
title | Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients |
title_full | Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients |
title_fullStr | Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients |
title_full_unstemmed | Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients |
title_short | Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients |
title_sort | patient selection and 30-day outcomes of sadi-s compared to rygb: a retrospective cohort study of 47,375 patients |
topic | Original Contributions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022408/ https://www.ncbi.nlm.nih.gov/pubmed/35445967 http://dx.doi.org/10.1007/s11695-022-06068-y |
work_keys_str_mv | AT verhoeffkevin patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients AT mocanuvalentin patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients AT jogiatuzair patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients AT forbeshayley patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients AT switzernoahj patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients AT birchdanielw patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients AT karmalishahzeer patientselectionand30dayoutcomesofsadiscomparedtorygbaretrospectivecohortstudyof47375patients |